Two very different procedures
| Vasectomy | Tubal sterilisation | |
|---|---|---|
| Principle | Cutting or blocking the vas deferens, which carry sperm (WHO/JHU handbook) | Blocking or removing the fallopian tubes, which carry the egg |
| Procedure | 15 to 20 minutes (NHS, 2024), under local anaesthetic, as a day case. Usually by the no-scalpel technique (AUA, 2026) | Surgery under general anaesthetic, most often laparoscopic (NHS, 2024) |
| Effect | Delayed: about three months (WHO/JHU handbook) and some twenty ejaculations | Immediate |
| Check | A confirmatory semen analysis is essential before stopping other contraception (AUA, 2026) | No check needed |
| Failure | about 1 in 2,000 once azoospermia is confirmed (AUA, 2026) | about 1 in 200 in the first year (WHO/JHU handbook); recent cohorts give higher figures |
| Recovery | A few days | One to two weeks |
The asymmetry is striking: vasectomy is simpler, safer, more effective and cheaper than female sterilisation (WHO/JHU handbook). It is nonetheless far less often performed in most countries — a gap explained by perception, not by medicine.
Two clarifications on the failure figures
For vasectomy, the 1 in 2,000 figure applies after a semen analysis has confirmed the absence of sperm. Almost all real failures happen before that check (WHO/JHU handbook), in couples who stopped other contraception too soon.
For tubal sterilisation, the classic 1 in 200 for the first year is now debated: large recent cohorts find markedly higher pregnancy rates, in the order of several per cent at ten years (WHO/JHU handbook). The reliability gap with vasectomy is therefore probably wider still than reference tables suggest.
In France: men are now sterilised more often than women
According to the EPI-PHARE group (ANSM and the national health insurance fund), which analysed reimbursement data, the annual number of vasectomies rose from 1,940 in 2010 to 30,288 in 2022, a fifteen-fold increase (EPI-PHARE, 2024). Over the same period, female sterilisations fell by half, from 45,138 in 2013 to 20,325 in 2022 (EPI-PHARE, 2024). For the first time, male sterilisations exceeded female ones in 2021 and in 2022: three for every two in 2022 (EPI-PHARE, 2024). The national health insurance fund links the fall among women in part to the withdrawal of the Essure implants from the market in 2017 (Assurance Maladie, 2024).
An EPI-PHARE update, published on 27 August 2026, extends the curve to 2025: 46,826 vasectomies in 2023, 53,955 in 2024 and 57,666 in 2025, or 280 per 100,000 inhabitants (EPI-PHARE, 2026). The 2022 figure appears there as 32,172, against 30,288 in the 2024 report, and the incidence has increased 1.8-fold since 2022 (EPI-PHARE, 2026): the two series therefore cannot be compared to the exact unit. This update covers vasectomies, and EPI-PHARE stresses that this rise runs counter to the global trend, which is downward (EPI-PHARE, 2026).
The average age of men at the time of the procedure fell from 44 to 41 between 2010 and 2022 (EPI-PHARE, 2024); the median age is 40 in 2025, stable since 2021 (EPI-PHARE, 2026). EPI-PHARE also observes social disparities: higher uptake in the middle class, lower among beneficiaries of the solidarity health supplement (complémentaire santé solidaire) (EPI-PHARE, 2026).
The path in France: two consultations and four months of reflection
Sterilisation for contraceptive purposes is only possible for an adult, with no condition of age beyond 18, number of children or marital status (Ameli, 2024). It is governed by articles L. 2123-1 and L. 2123-2 of the Public Health Code, which stem from the law of 4 July 2001 (Ministry of Health, 2025).
- First consultation: the doctor presents all the reversible methods as well as permanent contraception, and hands over an information booklet (Ameli, 2024). A doctor is never obliged to perform the procedure, but must state their refusal at this first consultation (Ministry of Health, 2025).
- Four-month reflection period before the second consultation (Ameli, 2024).
- Second consultation: the person confirms the request in writing (Ameli, 2024).
- Procedure in a healthcare facility, most often as day surgery under local anaesthesia, sometimes under general anaesthesia; an overnight hospital stay is generally not needed (HAS, 2019).
Complications are rare: scrotal haematoma, infection, pain (Ameli, 2024). In the EPI-PHARE study published in a scientific journal, they affected 1.0% of men, and 6.8% had had sperm frozen before the procedure (Roland et al., 2025).
The effect is not immediate: the absence of sperm (azoospermia) is only reached after 8 to 16 weeks and about twenty ejaculations, and additional contraception remains essential in the meantime (Ameli, 2024). A semen analysis checks the result (HAS, 2019). In the French data, 64.7% of the men operated on had a follow-up semen analysis (Roland et al., 2025).
The Ministry of Health describes vasectomy as highly effective (around 99%) and asks that it be regarded as irreversible: reopening the vas deferens is a complex surgical procedure that does not restore fertility in the majority of cases. Sperm banking is possible, for example in a sperm study and preservation centre (CECOS), without guaranteeing a pregnancy (Ministry of Health, 2025).
Three misconceptions about vasectomy
- "It is castration." No: vasectomy has no effect on physical appearance and changes neither erection, nor ejaculation, nor desire, nor sexual pleasure (HAS, 2019).
- "It is major surgery." It is most often done as day surgery, under local anaesthesia (HAS, 2019), and complications are rare (Ameli, 2024).
- "We can always go back." No: the procedure must be regarded as irreversible (Ministry of Health, 2025), and a four-month reflection period precedes it (Ameli, 2024).
What sterilisation does not change
- Vasectomy: no effect on erection, desire (WHO/JHU handbook), testosterone, sensation or the volume of the ejaculate — sperm make up a tiny fraction of it. It is not castration (WHO/JHU handbook), and the confusion remains widespread.
- Tubal sterilisation: it does not bring on the menopause, does not stop periods and does not change hormone production (NHS, 2024).
- Neither protects against sexually transmitted infections (NHS, 2024).
The question of reversal
Reversal surgery exists, but its outcome is never guaranteed (NHS, 2024): pregnancy rates vary widely with the original technique, the time elapsed and age (AUA, 2026). It is often expensive and rarely funded (WHO/JHU handbook). Sterilisation is decided on as permanent — that is the only honest way to present it.
One alternative exists for men: sperm storage before the procedure (AUA, 2026), whose conditions and cost vary by country.
Regret, and what predicts it
Regret is uncommon overall but not absent, and two factors predict it robustly: a young age at the time of the decision (WHO/JHU handbook) and a decision taken in a moment of crisis — just after a birth, a separation, or under pressure from a partner (WHO/JHU handbook). Having no children is also associated with more frequent regret, without ruling out the procedure. This is one reason a waiting period is imposed almost everywhere between the first consultation and the procedure.
State of research
The French data on vasectomy are descriptive: drawn from the national health data system, they count procedures but say nothing about the partners or the number of children of the men operated on (Roland et al., 2025). They therefore say nothing about regret or motivations. According to the national health insurance fund, France seems to be gradually catching up, while still lagging behind the countries furthest ahead on this front (Assurance Maladie, 2024). The most recent figures, up to 2025, come from the August 2026 EPI-PHARE update (EPI-PHARE, 2026), which covers vasectomies only.
The rules vary from country to country
Minimum age, mandatory waiting period, whether a spouse's consent is required, a required number of children, funding: all of this is national law, and differs profoundly between countries — including neighbouring ones. One permanent device fitted through the cervix, once offered, has been withdrawn worldwide (ANSM, 2017) (FDA, 2022). For France, see "The path in France" above; see the country pages for the rules that apply elsewhere.
